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peak velocity (SPV) at diagnosis was 25.2±16.1 cm/s, and 15.82±10.5 at 6 months. Of those with persistent Doppler signal, 2
were big, 1 developed metastasis and 4 regressed. 8 avascular tumors at diagnosis experienced new vascularization: 1 recurred, 7
regressed and 4 of them developed neovascular glaucoma (NVG). Reduction in thickness was bigger when tumors vascularized,
lost Doppler signals. SPV decreased signiﬁcantly at 6 months (p=0.028), but not the diastolic peak (p=0.116).
Conclusion. Doppler scan is an important tool in the management of melanoma after plaque. Majority of tumors lost its Doppler
signal in the ﬁrst 6 months. Persistent intratumoral vessels are associated to big tumour size, recurrence or vascular congestion.
New vascularized cases can be explained by persistence of old vessels, recurrence or NVG. We recommend supporting these
ﬁndings with the current tests in direct ophthalmoscopy and ultrasound.
http://dx.doi.org/10.1016/j.rpor.2013.03.705
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Purpose. The aim of this study was to evaluate the efﬁcacy and toxicity of combining external beam radiation therapy (EBRT) and
high-dose-rate brachytherapy (HDRB) as a boost, in terms of biochemical relapse in patient (pts) with prostate cancer.
Methods and materials. From 2002 to July 2012, 377 pts with a diagnosis of intermediate-high risk prostate cancer were treated with
EBRT followed by supplemental HDRB. The characteristics were: mean age 65.78 (41–86 years), Gleason was 7 in 191 pts (50.7%)
and 8 or higher in 131 (35%), 226 pts. (60%) had a PSA>10ng/ml, T3 stage 263 pts (70%), T2 64 (17%) and T1 49 (13%). The EBRT
total mode dose was 60.0Gy (45–70Gy) on prostate and seminal vesicles. 120 pts (31%) also received a mode of 46Gy (45–50Gy)
on minor pelvis. All pts received a mode single-fraction of 9Gy (9–15) of HDRB-boost. Complete androgen deprivation was given
to 353 pts (93.63%).
Results. The mean follow-up was 48.72 months (6–126). The 5 and 7-year actuarial overall survival was 88% (CI 95%: 84–92) and
75% (CI 95%: 68–83). Cause speciﬁc survival at 5 and 7 years was 98% (CI 95%: 97–99) and 97% (CI 95%: 96–98) respectively. Disease
free survival was 93% (CI 95%: 89–97) and 91% (CI 95%: 87–95). The 5 and 7-year biochemical free relapse was 91% (CI 95%: 87–95)
and 89% (CI 95%: 83–95). The gastrointestinal grade 2–3 late-toxicity was observed in 17 pts (4.6%) and 6 pts (0.8%) respectively.
Genitourinary grade 2–3 toxicity was observed in 46 pts (12.2%) and 3 pts (1.6%).
Conclusion. The ﬁndings after long-term follow-up of intermediate-high risk prostate cancer pts treated with EBRT plus supple-
mental HDRB boost conﬁrmed the effectiveness of this fractionation schedule in terms of discomfort, treatment-related toxicity
and biochemical control.
http://dx.doi.org/10.1016/j.rpor.2013.03.706
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Objective. To evaluate the feasibility and toxicity of high-dose-rate (HDR)-brachytherapy (BT) as monotherapy in a prospective
clinical trial consisting of a single implant and two fractions (13.5Gy×2) for a total dose of 27Gy, delivered within 1 day for
localized prostate cancer. We report the acute and early chronic genitourinary (GU) and gastrointestinal toxicity (GI).
Methods and materials. A total of 78 patientswere treated betweenNovember 2010 andDecember 2012. A Phase II trial ofmonother-
apy HDRB performed for localized prostate cancer using a single implant and two fractions (13.5Gy×2) for a total dose of 27Gy
calculated to be radiobiology of HDRB regimens and BED to 261Gy in 2Gy fractions (˛/ˇ ratio of 1.5Gy). All patients had clinical
Stage T2c or less (AJCC, 5th edition), Gleason score 4–7 (3 + 4), PSA level of ≤15ng/mL. CT scans were done for dosimetry. GU and
GI toxicity were evaluated by CTCAE V 3.0. The highest toxicity scores and self-reported sexual function (patients without BAC)
were recorded during follow-up.
Results. Median follow-up was 9.32 months (range: 2.23–26.07). Grade 1–2 GU acute toxicity was 20.51%, mainly frequency/urgency
(14.1%), dysuria (7.7%), hematuria, dribbling/hesitancy (1.3%). One patient required a Foley catheter during 1 week. No acute GI
toxicities were recorded. The most common early chronic toxicity was Grade 1 urinary frequency/urgency in 1.3% and Grade 2
dysuria in 7.7% of patients; 1 patient had Grade 2 rectal bleeding, 1 had Grade 4, requiring RTU. Twenty-eight patients without
BAC reported potency before therapy; No one of them developed sexual impotence.
Conclusions. A single implant HDR-BT to 27Gy in two fractions within 1 day for localized prostate cancer is feasible with minimal
acute or late toxicity. Longer follow-up is needed to conﬁrm these encouraging early results.
http://dx.doi.org/10.1016/j.rpor.2013.03.707
